FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 194 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most... May 15, 2020 Cancer Moonshot℠ Workshop Highlights Recent Research Advances March 4, 2020 After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Sorafenib October 7, 2022 Load more HOT NEWS Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... The Doctor Will See You Now…On the Screen Having Cancer as a Young Adult Put Me on a Path...
